Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

Recent & Breaking News (TSXV:BTI)

Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research

GlobeNewswire October 22, 2020

Bioasis Announces Issuance of US Patent Relating to xB³(TM) Platform Technology for The Delivery of Therapeutic Agents Across the Blood-Brain Barrier

GlobeNewswire October 20, 2020

Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020

Business Wire July 27, 2020

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

Business Wire July 9, 2020

Bioasis Announces Stock Option Grants

Business Wire July 7, 2020

Bioasis signs megadeal with Chiesi Group to take drug delivery technology global

Oliver Gray July 2, 2020

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

Business Wire June 29, 2020

IIROC Trading Resumption - BTI

Canada NewsWire June 29, 2020

Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

Business Wire June 29, 2020

IIROC Trading Halt - BTI

Canada NewsWire June 29, 2020

Bioasis Announces Conversion of Debenture Interest Into Equity

Business Wire June 24, 2020

Bioasis Announces Analyst Coverage Initiated by Edison Group

Business Wire June 17, 2020

Bioasis Completes Redemption of 15% Unsecured Debentures With Unanimous Debentureholder Approval

Business Wire April 6, 2020

Bioasis Announces Shares for Debt Transaction

Business Wire April 1, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Bioasis Announces Proposed Redemption of 15% Unsecured Debentures

Business Wire March 6, 2020

Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer

Business Wire March 4, 2020

Growth Company Investor Presentations Now Available for On-Demand Viewing

Canada NewsWire February 24, 2020

Bioasis to Present at the OTC Markets 2020 Virtual Investor Conference

PR Newswire February 19, 2020

Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

PR Newswire February 14, 2020